Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology

Reuters

2025/08/04

<a href="https://laohu8.com/S/MDCX">Medicus Pharma Ltd.</a> Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology

Medicus Pharma Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array $(MNA)$ delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 261071) on August 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556981386"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556981386\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556981386?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556981386","market":"us","top_or_hot":-1,"title":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array <a href=\"https://laohu8.com/S/MNA\">$(MNA)$</a> delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a> Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 261071) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-04 19:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array <a href=\"https://laohu8.com/S/MNA\">$(MNA)$</a> delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a> Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 261071) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL34xW2N:1","article_id":"2556981386","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556981386","pubTimestamp":1754307065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology. Medicus Pharma Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array  delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MDCX":"Medicus Pharma Ltd."},"translate_title":"Medicus Pharma Ltd.宣布利用创新微针阵列技术进行热稳定mRNA疫苗的新临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCX":0.9},"content_text":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology\n    \n\nMedicus Pharma Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array $(MNA)$ delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 261071) on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}